{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:14:20Z","timestamp":1787242460603,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H27-28 Nanchi, etc. (Nan)- General-002; H27-Nanchi, etc. (Nan)-General-008; H29-Nanchi, etc. (Nan)-General-008; H29-Nanchi, etc. (Nan)-General-019; H29-Nanchi, etc. (Nan)-General-058"],"award-info":[{"award-number":["H27-28 Nanchi, etc. (Nan)- General-002; H27-Nanchi, etc. (Nan)-General-008; H29-Nanchi, etc. (Nan)-General-008; H29-Nanchi, etc. (Nan)-General-019; H29-Nanchi, etc. (Nan)-General-058"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H27-Nanchi, etc. (Nan)- General-002; H27-Nanchi, etc. (Nan)-General-008; H29-Nanchi, etc. (Nan)-General-019"],"award-info":[{"award-number":["H27-Nanchi, etc. (Nan)- General-002; H27-Nanchi, etc. (Nan)-General-008; H29-Nanchi, etc. (Nan)-General-019"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["Grant No.17591060 and 15K09510"],"award-info":[{"award-number":["Grant No.17591060 and 15K09510"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004043","name":"Kanazawa Medical University","doi-asserted-by":"publisher","award":["S2004-16, S2007-5, H2011-11, AR2012-06"],"award-info":[{"award-number":["S2004-16, S2007-5, H2011-11, AR2012-06"]}],"id":[{"id":"10.13039\/501100004043","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s12185-020-03008-3","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T08:02:39Z","timestamp":1600934559000},"page":"73-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan"],"prefix":"10.1007","volume":"113","author":[{"given":"Shino","family":"Fujimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1918-8635","authenticated-orcid":false,"given":"Hiroshi","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Nishikori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Nara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Kurose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohsuke","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazue","family":"Takai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadao","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"3008_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3960\/jslrt.53.57","volume":"53","author":"H Kawabata","year":"2013","unstructured":"Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, et al. Castleman-Kojima disease (TAFRO Syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop. 2013;53:57\u201361.","journal-title":"J Clin Exp Hematop"},{"key":"3008_CR2","first-page":"320","volume":"51","author":"K Takai","year":"2010","unstructured":"Takai K, Nikkuni K, Shibuya H, Hashidate H. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki. 2010;51:320\u20135.","journal-title":"Rinsho Ketsueki"},{"key":"3008_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00432-019-03120-w","volume":"146","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Suo SS, Yang HJ, Zhou XP, You LS, Yu WJ, et al. Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study. J Cancer Res Clin Oncol. 2020;146:357\u201365.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3008_CR4","first-page":"253","volume":"12","author":"Z Islamoglu","year":"2018","unstructured":"Islamoglu Z, Duman AE, Sirin G, Yilmaz H, Menguc MU, Ercetin Y, et al. TAFRO syndrome: a case report from Turkey and review of the literature. Int J Hematol Oncol Stem Cell Res. 2018;12:253\u20139.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"3008_CR5","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00277-018-3269-x","volume":"97","author":"W Owattanapanich","year":"2018","unstructured":"Owattanapanich W, Pholmoo W, Pongpruttipan T, Siritanaratkul N. High proportion of TAFRO syndrome in Thai adult Castleman\u2019s disease patients: a 10-year experience. Ann Hematol. 2018;97:1019\u201326.","journal-title":"Ann Hematol"},{"key":"3008_CR6","first-page":"e4946","volume":"11","author":"JL Miatech","year":"2019","unstructured":"Miatech JL, Patel NR, Latuso NQ, Ellipeddi PK. TAFRO syndrome: a case of significant endocrinopathy in a Caucasian patient. Cureus. 2019;11:e4946.","journal-title":"Cureus"},{"key":"3008_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3389\/fmed.2017.00149","volume":"4","author":"C Louis","year":"2017","unstructured":"Louis C, Vijgen S, Samii K, Chalandon Y, Terriou L, Launay D, et al. TAFRO syndrome in Caucasians: a case report and review of the literature. Front Med (Lausanne). 2017;4:149.","journal-title":"Front Med (Lausanne)"},{"key":"3008_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2162-3619-4-3","volume":"4","author":"S Tedesco","year":"2015","unstructured":"Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A, et al. Successful treatment of a Caucasian case of multifocal Castleman\u2019s disease with TAFRO syndrome with a pathophysiology targeted therapy\u2014a case report. Exp Hematol Oncol. 2015;4:3.","journal-title":"Exp Hematol Oncol"},{"key":"3008_CR9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/ajh.25554","volume":"94","author":"S Fujimoto","year":"2019","unstructured":"Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Takai K, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 2019;94:975\u201383.","journal-title":"Am J Hematol"},{"key":"3008_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s12185-016-1979-1","volume":"103","author":"Y Masaki","year":"2016","unstructured":"Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016;103:686\u201392.","journal-title":"Int J Hematol"},{"key":"3008_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3960\/jslrt.53.87","volume":"53","author":"N Iwaki","year":"2013","unstructured":"Iwaki N, Sato Y, Takata K, Kondo E, Ohno K, Takeuchi M, et al. Atypical hyaline vascular-type castleman\u2019s disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. J Clin Exp Hematop. 2013;53:87\u201393.","journal-title":"J Clin Exp Hematop"},{"key":"3008_CR12","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.2169\/internalmedicine.52.9482","volume":"52","author":"H Kawabata","year":"2013","unstructured":"Kawabata H, Kotani S, Matsumura Y, Kondo T, Katsurada T, Haga H, et al. Successful treatment of a patient with multicentric Castleman\u2019s disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med. 2013;52:1503\u20137.","journal-title":"Intern Med"},{"key":"3008_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3960\/jslrt.53.79","volume":"53","author":"Y Masaki","year":"2013","unstructured":"Masaki Y, Nakajima A, Iwao H, Kurose N, Sato T, Nakamura T, et al. Japanese variant of multicentric castleman\u2019s disease associated with serositis and thrombocytopenia\u2014a report of two cases: is TAFRO syndrome (Castleman\u2013Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop. 2013;53:79\u201385.","journal-title":"J Clin Exp Hematop"},{"key":"3008_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1471-2431-14-139","volume":"14","author":"I Kubokawa","year":"2014","unstructured":"Kubokawa I, Yachie A, Hayakawa A, Hirase S, Yamamoto N, Mori T, et al. The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman\u2019s disease. BMC Pediatr. 2014;14:139.","journal-title":"BMC Pediatr"},{"key":"3008_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1620\/tjem.236.289","volume":"236","author":"Y Konishi","year":"2015","unstructured":"Konishi Y, Takahashi S, Nishi K, Sakamaki T, Mitani S, Kaneko H, et al. Successful treatment of TAFRO syndrome, a variant of multicentric Castleman\u2019s disease, with cyclosporine a: possible pathogenetic contribution of interleukin-2. Tohoku J Exp Med. 2015;236:289\u201395.","journal-title":"Tohoku J Exp Med"},{"key":"3008_CR16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s12185-016-1978-2","volume":"103","author":"S Fujiwara","year":"2016","unstructured":"Fujiwara S, Mochinaga H, Nakata H, Ohshima K, Matsumoto M, Uchiba M, et al. Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. Int J Hematol. 2016;103:718\u201323.","journal-title":"Int J Hematol"},{"key":"3008_CR17","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1172\/JCI126091","volume":"130","author":"DC Fajgenbaum","year":"2019","unstructured":"Fajgenbaum DC, Langan RA, Japp AS, Partridge HL, Pierson SK, Singh A, et al. Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019;130:4451\u201363.","journal-title":"J Clin Invest"},{"key":"3008_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12185-019-02780-1","volume":"111","author":"Y Masaki","year":"2020","unstructured":"Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y, et al. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020;111:155\u20138.","journal-title":"Int J Hematol"},{"key":"3008_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3008_CR20","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","volume":"132","author":"F van Rhee","year":"2018","unstructured":"van Rhee F, Voorhees P, Dispenzieri A, Fossa A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132:2115\u2013244.","journal-title":"Blood"},{"key":"3008_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3960\/jslrt.19021","volume":"59","author":"Y Masaki","year":"2019","unstructured":"Masaki Y, Kawabata H, Fujimoto S, Kawano M, Iwaki N, Kotani T, et al. Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan. J Clin Exp Hematop. 2019;59:175\u20138.","journal-title":"J Clin Exp Hematop"},{"key":"3008_CR22","first-page":"519","volume":"81","author":"T Matsuhisa","year":"2019","unstructured":"Matsuhisa T, Takahashi N, Nakaguro M, Sato M, Inoue E, Teshigawara S, et al. Fatal case of TAFRO syndrome associated with over-immunosuppression: a case report and review of the literature. Nagoya J Med Sci. 2019;81:519\u201328.","journal-title":"Nagoya J Med Sci"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03008-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-03008-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03008-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T01:13:19Z","timestamp":1632445999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-03008-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["3008"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-03008-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]},"assertion":[{"value":"13 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Kawabata reports grants from Ministry of Health, Labor, and Welfare (MHLW) of Japan, during the conduct of the study. Dr. Nishikori reports personal fees from Eisai Co., Ltd., grants from Eisai Co., Ltd., grants from Sumitomo Dainippon Pharma Co., Ltd., outside the submitted work. Dr. Tsukamoto reports scholarship donation from Kyowa Hakko Kirin Co., Ltd., outside the submitted work. Dr. Aoki reports personal fees from AbbVie GK., personal fees from Janssen Pharmaceutical K.K, outside the submitted work. Dr. Masaki reports grants from Ministry of Health, Labor, and Welfare (MHLW) of Japan, grants from Ministry of Education, Culture, Sports, Science and Technology, grants from Kanazawa Medical University, grants from Eisai Co., Ltd., grants from Kyowa Hakko Kirin Co., Ltd., grants from Astellas Pharma Inc., grants from Ono Pharmaceutical Co. Ltd., grants from Pfizer Seiyaku K. K., during the conduct of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}